Shuren: LDT Reliability Critical To Precision Medicine Initiative
This article was originally published in The Gray Sheet
Executive Summary
The head of CDRH said the agency's efforts to oversee laboratory developed tests are critical to ensuring reliability of genetic tests in conjunction with the president's Precision Medicine Initiative.
You may also be interested in...
Clinical Labs Lawyer Up In Battle Over LDTs
ACLA has recruited Laurence Tribe and Paul Clement, two prominent constitutional legal guns with Supreme Court expertise, to fight FDA over its proposed lab-developed test guidance. The announcement is perhaps the lab industry's most high profile move yet to oppose FDA's plan to regulate lab-developed test services under the device statute with a risk-based phase-in plan.
FDA Releases LDT Regulatory Framework, Notification Draft Guidances
Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.